Pig Interferon γ,IFN-γ ELISA Kit

Promotion
Code CSB-E06794p-IS
Size 96T,5×96T,10×96T
Price Request a Quote
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >>
Interested in a trial size? Please leave a message below.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Alternative Names
IFNGInterferon gamma ELISA Kit; IFN-gamma ELISA Kit
Abbreviation
Uniprot No.
Species
Sus scrofa (Pig)
Sample Types
serum, plasma, tissue homogenates
Detection Range
6.25 pg/mL-400 pg/mL
Sensitivity
3.12 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of pig IFN-γ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

 

Sample

Serum(n=4)

1:1

Average %

101

Range %

94-108

1:2

Average %

92

Range %

85-99

1:4

Average %

96

Range %

91-101

1:8

Average %

93

Range %

86-99

Recovery

The recovery of pig IFN-γ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type

Average % Recovery

Range

Serum (n=5)

90

86-96

EDTA plasma (n=4)

92

87-98

Typical Data

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

pg/ml

OD1

OD2

Average

Corrected

400

2.687

2.634

2.660

2.547

200

1.913

1.967

1.940

1.827

100

1.233

1.188

1.211

1.097

50

0.659

0.629

0.644

0.531

25

0.358

0.321

0.340

0.226

12.5

0.223

0.233

0.228

0.115

6.25

0.176

0.184

0.180

0.067

0

0.115

0.111

0.113

 

Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Shelf Life
6 months

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation.
Gene References into Functions
  1. The regulatory effect of IFN-gamma on CYP3A29 expression is mediated via PXR. PMID: 25413352
  2. Mapping of QTL for mycoplasma and tetanus antibodies and IFNgamma. PMID: 20567833
  3. Data show taht the expression of PoIFN-gamma in insect cells was confirmed by Western Blot, indirect immunofluorescence assay and indirect ELISA. PMID: 17577980
  4. IFNgamma production from the frozen peripheral blood mononuclear cells was significantly higher than that from the fresh ones. PMID: 19766617
  5. Translational control of IL-18 expression by its 5'-UTR limits production of IL-18, resulting in restricted expression of mRNA and protein IFN-gamma in this model of crescentic glomerulonephritis(GN). Might amplify CD8+-mediated macrophage-dependent GN. PMID: 12787406
  6. selective changes in immature crypt cells induced by IFN-gamma bound to extracellular matrix could contribute to inappropriate responsiveness to commensal bacteria in inflammatory bowel diseases PMID: 15894119
  7. A functional single nucleotide polymorphism is reported in the coding region of IFN-gamma cDNA that markedly reduces antiviral activity of the IFN-gamma protein. PMID: 17416419
  8. The expression of IFN-gamma in recombiannt Lactococcus lactis as a tool for investigating downregulation of allergic predisposition of pigs to experimental food allergy is reported. PMID: 18164876

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Type II (or gamma) interferon family
Tissue Specificity
Released primarily from activated T lymphocytes.
Database Links
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*